Shares of Juno Therapeutics (JUNO) soared as high as 16% in trading Tuesday on reports that AstraZeneca’s (AZN) CEO said he saw Juno as a potential acquisition target. Bloomberg came out with the full story on its interview with AstraZeneca CEO Pascal Soriot in the early afternoon, but Juno’s stock first jumped in midmorning when Bloomberg terminal subscribers got a few tidbits that were then passed along through StreetInsider and other media
Five drug companies including NewLink Genetics (NLNK), Juno Therapeutics (JUNO) and Intrexon (XON) reported quarterly results after the close on Monday, but some investors seemed to be more focused on the companies’ development updates than their actual earnings. Depomed Misses Depomed (DEPO) widened its loss to an adjusted 13 cents a share from last year’s 1-cent loss. Analysts were expecting earnings of a penny. Revenue fell 58% to $32.2
Earnings season is winding down, but there are still top stocks due to report, including drug giant Actavis (ACT), one of several drug stocks reporting earnings that day, including Intrexon (XON), Impax Laboratories (IPXL) and Juno Therapeutics (JUNO). Actavis is on the IBD 50 list of the very best stocks. Three other IBD 50 stocks — Regeneron Pharmaceuticals (REGN), Monster Beverage (MNST) and Autohome (ATHM) dished out results in the latest